Article Contents ::
- 1 Details About Generic Salt :: Letrozol
- 2 Main Medicine Class::
- 3 (let-ROW-zahl) Femara Tablets 2.5 mg. Class: Nonsteroidal aromatase inhibitor
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Letrozol
Main Medicine Class::
(let-ROW-zahl)
Femara
Tablets
2.5 mg.
Class: Nonsteroidal aromatase inhibitor
Drugs Class ::
Action A nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. Elimination half-life is approximately 2 days. It is weakly protein bound. Renal excretion is the major pathway of letrozole clearance.
Indications for Drugs ::
Indications Advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy; first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic cancer.
Drug Dose ::
Route/Dosage
Breast Cancer Adults: PO 2.5 mg once daily (tablets).
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Hepatic function impairment: Use caution in patients with severe hepatic dysfunction.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CARDIOVASCULAR: Chest pain; hypertension; peripheral edema. CNS: Decreased appetite; fatigue; headache; insomnia; somnolence; dizziness; asthenia; weakness. DERMATOLOGIC: Rash; pruritis; alopecia. GI: Nausea and vomiting; constipation; diarrhea; abdominal pain; anorexia; dyspepsia. GU: Sexual inactivity; atrophy of the female reproductive organs; breast pain. METABOLIC: Hot flashes; weight gain; hypercholesterolemia; weight loss. RESPIRATORY: Dyspnea; coughing. OTHER: Viral infections; musculoskeletal pain; arthralgia; flu-like symptoms.
Drug Mode of Action ::
Action A nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. Elimination half-life is approximately 2 days. It is weakly protein bound. Renal excretion is the major pathway of letrozole clearance.
Drug Interactions ::
Interactions
Contraceptives, oral May alter the efficacy of oral contraceptives.
Tamoxifen Plasma concentrations of letrozole may be decreased.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note history of liver disease.
- Monitor for GI, CNS, musculoskeletal, and general body side effects. Inform health care provide if noted and significant.
Drug Storage/Management ::
Administration/Storage
- Store at controlled room temperature (59° and 86°F).
- Administer PO; may be taken without regard to meals.
Drug Notes ::
Patient/Family Education
- Explain name, dose, action, and potential side effects of drug.
- Review dosing schedule with patient.
- Advise patient that medication can be taken without regard to meals, but to take with food if GI upset occurs.
- Advise patient that if a dose is missed, take it as soon as possible, but if close to the next dose, do not double the dose to catch up and take the next dose as scheduled.
- Advise patient to report persistent or intolerable side effects to health care provider.
- Instruct patient to not take any prescription or OTC medications or dietary supplements unless advised to do so by the health care provider.
- Advise patient that follow-up examinations and lab tests will be required to monitor therapy and to keep appointments.